scholarly journals Gut Microbiome in Inflammatory Bowel Disease and Other Chronic Immune-Mediated Inflammatory Diseases

2017 ◽  
Vol 2 (2) ◽  
pp. 116-123 ◽  
Author(s):  
Charles N. Bernstein ◽  
Jessica D. Forbes
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Gut Microbiome ◽  
Inflammatory Diseases ◽  
Immune Mediated ◽  
Inflammatory Bowel

scholarly journals Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise

2021 ◽  
Author(s):  
Silvio Danese ◽  
Laurent Peyrin-Biroulet
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tyrosine Kinase ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Janus Kinase ◽  
Type I ◽  
Tyrosine Kinase 2 ◽  
Immune Mediated ◽  
Inflammatory Bowel

Abstract Conventional systemic and biologic agents are the mainstay of inflammatory bowel disease (IBD) management; however, many of these agents are associated with loss of clinical response, highlighting the need for effective, novel targeted therapies. Janus kinase (JAK) 1-3 and tyrosine kinase 2 (TYK2) mediate signal transduction events downstream of multiple cytokine receptors that regulate targeted gene transcription, including the interleukin-12, interleukin-23, and type I interferon receptors for TYK2. This review summarizes the role of TYK2 signaling in IBD pathogenesis, the differential selectivity of TYK2 inhibitors, and the potential clinical implications of TYK2 inhibition in IBD. A PubMed literature review was conducted to identify studies of JAK1-3 and TYK2 inhibitors in IBD and other immune-mediated inflammatory diseases. Key efficacy and safety information was extracted and summarized. Pan-JAK inhibitors provide inconsistent efficacy in patients with IBD and are associated with toxicities resulting from a lack of selectivity at therapeutic dosages. Selective inhibition of TYK2 signaling via an allosteric mechanism, with an agent that binds to the regulatory (pseudokinase) domain, may reduce potential toxicities typically associated with JAK1-3 inhibitors. Deucravacitinib, a novel, oral, selective TYK2 inhibitor, and brepocitinib and PF-06826647, TYK2 inhibitors that bind to the active site in the catalytic domain, are in development for IBD and other immune-mediated inflammatory diseases. Allosteric TYK2 inhibition is more selective than JAK1-3 inhibition and has the potential to limit toxicities typically associated with JAK1-3 inhibitors. Future studies will be important in establishing the role of selective, allosteric TYK2 inhibition in the management of IBD.

scholarly journals Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases

2019 ◽  
Vol 14 (5) ◽  
pp. 680-685 ◽  
Author(s):  
Michaël Somers ◽  
Peter Bossuyt ◽  
Marc Ferrante ◽  
Harald Peeters ◽  
Filip Baert
Keyword(s):  
Inflammatory Bowel Disease ◽  
Research Group ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Safety Data ◽  
Position Statement ◽  
European Medicines Agency ◽  
Immune Mediated ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Abstract The emergence of biosimilars is generally considered as an opportunity to guarantee accessibility to affordable treatments and to enhance financial sustainability of national health systems. Since 2017, five biosimilars of adalimumab were approved by the European Medicines Agency [EMA] for use in inflammatory bowel disease: ABP 510, SB5, GP2017, FKB327, and MSB11022. In this position statement, the available efficacy and safety data of the different adalimumab biosimilars in immune-mediated inflammatory diseases are summarised. Furthermore, the Belgian IBD research group [BIRD] formulates statements concerning the use of adalimumab biosimilars in inflammatory bowel disease.

scholarly journals Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis

2020 ◽  
Vol 8 (1) ◽  
pp. e001220
Author(s):  
Jianhua Wu ◽  
Sarah L Mackie ◽  
Mar Pujades-Rodriguez
Keyword(s):  
Rheumatoid Arthritis ◽  
Type 2 Diabetes ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Population Based ◽  
Immune Mediated ◽  
Inflammatory Bowel ◽  
Dose Dependent

IntroductionIn immune-mediated inflammatory diseases, there is a lack of -estimates of glucocorticoid dose–response diabetes risk that consider changes in prescribed dose over time and disease activity.Research design and methodsPopulation-based longitudinal analysis of electronic health records from the UK Clinical Practice Research Datalink, linked to hospital admissions and the mortality registry (1998–2017). We included 100 722 adult patients without diabetes history, diagnosed with giant cell arteritis or polymyalgia rheumatica (n=32 593), inflammatory bowel disease (n=29 272), rheumatoid arthritis (n=28 365), vasculitis (n=6082), or systemic lupus erythematosus (n=4410). We estimated risks and HRs of type 2 diabetes associated with time-variant daily and total cumulative prednisolone-equivalent glucocorticoid dose using Cox regression methods.ResultsAverage patient age was 58.6 years, 65 469 (65.0%) were women and 8858 (22.6%) had a body mass index (BMI) ≥30 kg/m2. Overall, 8137 (8.1%) people developed type 2 diabetes after a median follow-up of 4.9 years. At 1 year, the cumulative risk of diabetes increased from 0.9% during periods of non-use to 5.0% when the daily prednisolone-equivalent dose was ≥25.0 mg. We found strong dose-dependent associations for all immune-mediated diseases, BMI levels and underlying disease duration, even after controlling for periods of active systemic inflammation. Adjusted HR for a <5.0 mg daily dose versus non-use was 1.90, 95% CI 1.44 to 2.50; range 1.70 for rheumatoid arthritis to 2.93 for inflammatory bowel disease.ConclusionsWe report dose-dependent risks of type 2 diabetes associated with glucocorticoid use for six common immune-mediated inflammatory diseases. These results underline the need for regular diabetic risk assessment and testing during glucocorticoid therapy in these patients.

P292 Immunomodulator and biological therapy are increased in inflammatory bowel disease patients with associated immune-mediated inflammatory diseases

2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S245-S246
Author(s):  
M J Garcia Garcia ◽  
M Pascual Mato ◽  
C Del Pozo Calzada ◽  
L Rasines Perez ◽  
B Castro Senosiain ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Biological Therapy ◽  
Inflammatory Diseases ◽  
Immune Mediated ◽  
Inflammatory Bowel

P626 Prevalence of different immune mediated inflammatory diseases in patients with inflammatory bowel disease. AQUILES study

2013 ◽  
Vol 7 ◽  
pp. S262 ◽  
Author(s):  
I. Marín-Jiménez ◽  
F. Gómez ◽  
J.P. Gisbert ◽  
J.L. Pérez-Calle ◽  
M. Luján ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Immune Mediated ◽  
Inflammatory Bowel

Prevalence of Different Immune-Mediated Inflammatory Diseases in Patients With Inflammatory Bowel Disease. AQUILES study

2012 ◽  
Vol 18 ◽  
pp. S36-S37
Author(s):  
S Tabernero ◽  
I Marín-Jiménez ◽  
F Gómez ◽  
J Pérez Gisbert ◽  
JL Pérez-Calle ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Immune Mediated ◽  
Inflammatory Bowel

scholarly journals P175 Fatty liver disease as a complication of immune-mediated inflammatory diseases: prevalence and risk factors in inflammatory bowel disease

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S225-S225
Author(s):  
M T Arias Loste ◽  
M J García García ◽  
J C Rodriguez-Duque ◽  
P Iruzubieta ◽  
C Rivas ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Liver Disease ◽  
General Population ◽  
Bowel Disease ◽  
Fatty Liver Disease ◽  
Independent Predictor ◽  
Inflammatory Diseases ◽  
Advanced Fibrosis ◽  
Immune Mediated ◽  
Inflammatory Bowel

Abstract Background Previous publications made by our group showed an increased prevalence of fatty liver disease (NAFLD) in immune-mediated inflammatory diseases (IMIDs). However, the existing data on inflammatory bowel disease (IBD) are contradictory. Hypothesis: the prevalence of NAFLD is increased in IBD independently of the presence of metabolic factors. Methods Cross-sectional case–control study. Cases: prospective cohort single-center IBD patients. Controls: random sample from general population (Ethon cohort) paired 1: 2 by age, sex, BMI and T2D diagnosis. The diagnosis of NAFLD has been established by transition elastography (TE) CAP and confirmed by liver biopsy. Results The study scheme is presented in the figure. The prevalence of NAFLD is higher in IBD vs. general population (p = 0.04) and is associated with age, BMI, sex and metabolic syndrome. More frequently, IBD patients with NAFLD presented with severe complications of IBD and to a lesser extent receive TNF therapy. There is a mean serum elevation of CRP, ESR and ferritin compared with IBD subjects without NAFLD. In multivariant analysis, IBD is an independent predictor of NAFLD (adjusted OR 1.31; p = 0.007). The NAFLD associated with IBD is less frequently associated with T2D than NAFLD in the general population, and has a higher proportion of subjects with advanced fibrosis (TE &gt; 8.7 kPa: 45/350 [12.9%] vs. 23/669 [3.4%]; p &lt; 0.0001) and mean value of TE is significantly higher (6.09 vs. 5.11 kPa; p &lt; 0.0001). Non-invasive fibrosis scores have a high NPV in the diagnosis of advanced fibrosis in IBD (FIB4: 88%; APRI: 87%; NFS: 88%; HepametFS: 87 %) Conclusion The prevalence of NAFLD is higher in IBD patients, with IBD being an independent predictor of NAFLD. Patients with IBD and NAFLD have a higher systemic inflammatory burden and this results in an increased risk of advanced fibrosis associated with IBD comparatively with the control NAFLD population.

scholarly journals P647 2-year incidence of new immune-mediated inflammatory diseases in patients with inflammatory bowel disease. The AQUILES study

2014 ◽  
Vol 8 ◽  
pp. S340-S341
Author(s):  
I. Marín-Jiménez ◽  
V. García ◽  
J. Pérez-Gisbert ◽  
J.L. Pérez-Calle ◽  
M. Luján ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Immune Mediated ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document